Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2008

View Archived Issues

Panacos presents update on HIV drug pipeline

AstraZeneca returns worldwide rights to Hsp90 drugs IPI-504 and IPI-493 to Infinity

Capstone presents positive safety results for AZX-100 in dermal scarring

Chroma presents positive phase II efficacy data for tosedostat in AML

First phase III results released for FTY-720, a novel oral therapy for MS

Impax discusses phase III IPX-056 trial results with FDA

BAY-73-4506 investigated for preclinical effects in multiple myeloma

Stelara approved in Canada for moderate to severe plaque psoriasis

Baxter treats first patient in phase I recombinant von Willebrand factor trial

Cylene commences phase II quarfloxin trial in carcinoid/neuroendocrine tumors

Lundbeck initiates phase III clinical trials with nalmefene for alcohol dependence

Synvista treats first patient in SYI-2074 trial for psoriasis

Vivus initiates phase III avanafil trial in erectile dysfunction

Genfit commences phase II GFT-505 trial in patients with prediabetes

Shionogi launches Pirespa in Japan

FDA approves Abbott's Trilipix for patients with mixed dyslipidemia

FDA approves Mozobil to mobilize hematopoietic stem cells in transplantation

Synosia initiates proof-of-concept trial of nitisinone in RLS

LCT reports results from preclinical rat studies of NeurotrophinCell in PD

High rate of response seen with pomalidomide and dexamethasone in relapsed multiple myeloma

AN-3520 as a potential treatment for human African trypanosomiasis

EXTEND, RAISE studies add to data on recently approved eltrombopag

Novel Syk inhibitor prevents heparin-induced thrombocytopenia in vivo

Recent patents describe novel agents for neuropsychiatric disorders

Recent Novartis patent discloses new therapeutic agents for transplant rejection

New contraceptive agents reported in recent Organon patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...